[go: up one dir, main page]

WO2008105533A1 - Agent stimulant la sécrétion d'adiponectine comprenant un composé capsinoïde - Google Patents

Agent stimulant la sécrétion d'adiponectine comprenant un composé capsinoïde Download PDF

Info

Publication number
WO2008105533A1
WO2008105533A1 PCT/JP2008/053637 JP2008053637W WO2008105533A1 WO 2008105533 A1 WO2008105533 A1 WO 2008105533A1 JP 2008053637 W JP2008053637 W JP 2008053637W WO 2008105533 A1 WO2008105533 A1 WO 2008105533A1
Authority
WO
WIPO (PCT)
Prior art keywords
stimulating agent
metabolic syndrome
mammal
adiponectin secretion
adiponectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/053637
Other languages
English (en)
Japanese (ja)
Inventor
Kaori Ono
Hitoshi Satoh
Yasufumi Furuhata
Naohiko Inoue
Yoshiko Matsunaga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of WO2008105533A1 publication Critical patent/WO2008105533A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention concerne une substance dont l'administration par voie orale à un mammifère permet d'augmenter la production et la sécrétion d'adiponectine et qui permet donc de prévenir ou d'améliorer un syndrome métabolique chez le mammifère. De façon spécifique, l'invention porte sur un agent stimulant la sécrétion d'adiponectine chez un mammifère. Ledit agent comprend un composé capsinoïde et/ou un produit de dégradation de celui-ci comme principe actif. L'agent stimulant la sécrétion d'adiponectine peut être utilisé dans une composition pharmaceutique orale pour le traitement d'un sujet souffrant d'un syndrome métabolique ou dans une composition pour prévenir et/ou améliorer un syndrome métabolique sans provoquer la diminution de la masse corporelle d'un sujet souffrant d'un syndrome métabolique.
PCT/JP2008/053637 2007-03-01 2008-02-29 Agent stimulant la sécrétion d'adiponectine comprenant un composé capsinoïde Ceased WO2008105533A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007051588 2007-03-01
JP2007-051588 2007-03-01

Publications (1)

Publication Number Publication Date
WO2008105533A1 true WO2008105533A1 (fr) 2008-09-04

Family

ID=39721355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/053637 Ceased WO2008105533A1 (fr) 2007-03-01 2008-02-29 Agent stimulant la sécrétion d'adiponectine comprenant un composé capsinoïde

Country Status (1)

Country Link
WO (1) WO2008105533A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013031729A1 (fr) * 2011-08-26 2013-03-07 国立大学法人大阪大学 Agent prophylactique/thérapeutique pour les complications vasculaires du diabète
EP2567959A1 (fr) 2011-09-12 2013-03-13 Sanofi Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs
EP2629774A4 (fr) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246478A (ja) * 1998-03-04 1999-09-14 Morinaga & Co Ltd エステル結合を有する新規なカプサイシノイド様物質
JP2001026538A (ja) * 1999-07-13 2001-01-30 Morinaga & Co Ltd 新規なカプサイシノイド様物質を含有する食品及び医薬組成物
JP2002114676A (ja) * 2000-10-06 2002-04-16 Morinaga & Co Ltd 新規なカプサイシノイド様物質を含有する持久力向上用組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246478A (ja) * 1998-03-04 1999-09-14 Morinaga & Co Ltd エステル結合を有する新規なカプサイシノイド様物質
JP2001026538A (ja) * 1999-07-13 2001-01-30 Morinaga & Co Ltd 新規なカプサイシノイド様物質を含有する食品及び医薬組成物
JP2002114676A (ja) * 2000-10-06 2002-04-16 Morinaga & Co Ltd 新規なカプサイシノイド様物質を含有する持久力向上用組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IWAI K. ET AL.: "Roles as metabolic regulators of the non-nutrients, capsaicin and capsiate, supplemented to diets", PROC. JAPAN ACAD., vol. 79, no. 7, 2003, pages 207 - 212, XP007909041, DOI: doi:10.2183/pjab.79b.207 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2629774A4 (fr) * 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel
WO2013031729A1 (fr) * 2011-08-26 2013-03-07 国立大学法人大阪大学 Agent prophylactique/thérapeutique pour les complications vasculaires du diabète
JPWO2013031729A1 (ja) * 2011-08-26 2015-03-23 国立大学法人大阪大学 糖尿病性心血管合併症の予防・治療剤
US9393224B2 (en) 2011-08-26 2016-07-19 Osaka University Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes
EP2567959A1 (fr) 2011-09-12 2013-03-13 Sanofi Dérivés d'amide d'acide 6-(4-Hydroxy-phényl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs

Similar Documents

Publication Publication Date Title
WO2009063222A3 (fr) Compositions solides
WO2009091576A3 (fr) Préparations parentérales d'agonistes de dopamine
WO2009045795A3 (fr) Formulations galéniques de composés organiques
WO2009006095A3 (fr) Forme pharmaceutique en tablettte à deux parties
WO2011107755A3 (fr) Administration immédiate / retardée de médicament
WO2008052044A3 (fr) Utilisation de formes de propofol pour traiter des maladies associees au stress oxydatif
WO2009008006A3 (fr) Compositions pharmaceutiques d'administration gastro-intestinale de médicaments
WO2008040534A3 (fr) Formes pharmaceutiques à base de film non muco-adhésif
WO2011079239A3 (fr) Comprimé de combinaison avec couche externe croquable
WO2011005811A8 (fr) Polythérapie pour le traitement du diabète
WO2011039768A3 (fr) Compositions pharmaceutiques pour réduire une libération massive induite par l'alcool
WO2009032870A3 (fr) Procédé pour traiter le stress oxydatif et améliorer la mémoire de travail par administration de ptérostilbène
WO2008157537A3 (fr) Compositions et procédés d'utilisation pour traiter ou prévenir des troubles liés aux lipides
WO2010066749A3 (fr) Comprimés d'ulipristal acétate
WO2012092594A3 (fr) Préparations utilisables en vue de la prévention et/ou du traitement topique de symptômes allergiques oraux provoqués par un contact oral avec des fruits et/ou des légumes
NZ589469A (en) Niacin and NSAID combination for reducing niacin-induced flushing
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2007012022A3 (fr) Forme posologique unitaire renfermant un melange d'ibuprofene et de famotidine
WO2009111611A3 (fr) Composés, compositions et méthodes pour le traitement de l’accumulation du polypeptide amyloïde des îlots (iapp) dans le diabète
PL2205279T3 (pl) Farmaceutyczna kombinacja aliskirenu i walsartanu
WO2010090494A3 (fr) Utilisation médicale de dérivés d'acide 5-benzylaminosalicylique ou de sels correspondants
WO2011037976A3 (fr) Formulations pharmaceutiques de pramipexole
WO2008008882A3 (fr) Modulateur du récepteur des glucocorticoïdes et procédés d'utilisation
WO2007145863A3 (fr) Formulation à libération prolongée de naltréxone
JP2009522376A5 (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08721057

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08721057

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP